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A previous study suggested that the CXCR2 (+1208) TT genotype was associated with increased risk of
systemic sclerosis (SSc). In the present study, we investigated the inﬂuence of variation in the CXCL8
and CXCR2 genes on susceptibility to SSc and combined the variant alleles of these genes to analyze their
effects on SSc.
Methods: One ﬁfty one patients with SSc and 147 healthy bone marrow donors were enrolled in a case-
control study. Blood was collected for DNA extraction; typing of CXCL8 (251) T/A and CXCR2 (+1208) T/
C genes was made by polymerase chain reaction with sequence speciﬁc primers (PCR-SSP), followed by
agarose gel electrophoresis.
Results: The CXCR2-TC genotype was signiﬁcantly less frequent in patients (23.8% versus 55.1% in con-
trols; P < 0.001, OR = 0.26, 95%CI = 0.15–0.43), whereas the CXCR2-CC genotype was signiﬁcantly more
frequent (44.4% versus 22.4% in controls; P < 0.001, OR = 2.76, 95%CI, 1.62–4.72). When CXCR2 and CXCL8
combinations were analyzed, the presence of CXCR2 T in the absence of CXCL8 A (CXCR2 T+/CXCL8 A)
was more frequent in patients than in controls (34.5% versus 3.5%; P < 0.001, OR = 14.50, 95%CI = 5.04–
41.40). However, CXCR2 TT and CXCL8 A were signiﬁcantly more common in controls (100%) than in
patients (58.3%) (P < 0.001). Likewise, the presence of CXCR2 TC and CXCL8 A was more frequent in con-
trols (95.1%) than in patients (75%) (P = 0.004). Furthermore, the CXCR2-CC genotype in CXCL8 A was
more frequent in patients (59.7% versus 0% in controls; P < 0.001, adjusted OR = 98.67, 95%CI = 6.04–
1610.8). In patients, a high frequency was observed in combination with the CXCL8 TA and AA genotypes
(P < 0.001; OR = 28.92), whereas in controls, there was a high frequency of combination with CXCL8 T
(P < 0.001; OR = 0.03) and TT (P < 0.001; OR = 0.01). Conclusions: These ﬁndings suggest a protective role
of CXCL8 (251) A in the CXCR2 (+1208) TT and TC genotypes and an increased risk of CXCL8 (251) A in
association with the CXCR2 (+1208) CC genotype in SSc patients.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Systemic sclerosis (SSc) is a complex disease that occurs in
genetically predisposed individuals who have encountered speciﬁc
environmental exposures and/or other stochastic factors [1]. It is
currently believed that the pathogenesis of SSc involves progres-
sion from an early inﬂammatory phase to ﬁbrosis of the connective
tissues, affecting the skin and internal organs [2], compounded byas de Porto Alegre, Serviço de
s 2350, Bairro Bom Fim, CEP
101 8340.
m), rmaxavier@hcpa.ufrgs.br
er OA license.immune disturbances suggestive of autoimmunity, which are char-
acterized by the presence of high serum levels of autoantibodies
[3].
Emerging data suggest that chemokines may be essential con-
tributors to tissue damage in scleroderma [4]. Chemokine recep-
tors belong to the rhodopsin-like superfamily of G protein-
coupled receptor, and their structure consists of seven a-helical
transmembrane domains. The term ‘‘CXC’’ comes from the chemo-
kine protein structure, where two N-terminal cysteine residues
that form a disulﬁde bond are separated by another amino acid [5].
IL-8, a proinﬂammatory cytokine also known as CXCL8, is part
of the CXC subgroup. CXCL8 binds to CXCR1 and CXCR2 receptors
and has several functions, mainly initiation of chemotaxis; induc-
tion of angiogenesis; stimulation of cell proliferation; mediation
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concentration in neutrophils, monocytes, T lymphocytes, baso-
phils, eosinophils, and keratinocytes; induction of histamine and
leukotriene release; stimulation of prostaglandin E2 production
by smooth muscle cells; and induction of leukocyte migration [6].
CXCR2 receptors are expressed on neutrophils, have 77% amino
acid identity and bind CXCL8 with high afﬁnity [7]. The CXCR2
gene is located on 2q35, and some of its polymorphisms have been
widely investigated in disease association studies. The three most
commonly investigated are the +785 polymorphism (C/T) located
in exon 3, which does not alter the amino acid sequence of the
coded protein, and polymorphisms +1208 (T/C) and +1440 (G/A),
which are located at the 30 untranslated region of the same exon.
Polymorphisms in the 30 untranslated region have the ability to al-
ter the processing, stability and translation of mRNA [8].
A previous study by Renzoni et al. suggested that the presence
of CXCR2 (+1208) TT is associated with SSc, and a subgroup analy-
sis revealed that this association is signiﬁcant regardless of the
presence of ﬁbrosing alveolitis. To conﬁrm these ﬁndings, the pres-
ent study was designed to investigate the potential association of
CXCR2 and CXCL8 genes with systemic sclerosis [9].
2. Methods
2.1. Patients and controls
151 patients with systemic sclerosis were prospectively evalu-
ated. All patients met the American College of Rheumatology
(ACR) criteria for SSc [10] or the criteria suggested by LeRoy and
Medsger for diagnosis of early forms of SSc [11]. All patients were
Brazilian; most had European and/or African ancestry and lived in
the metropolitan area of Porto Alegre, state of Rio Grande do Sul.
None of the patients had Asian or Native Brazilian ancestry. Pa-
tients with overlapping syndromes were excluded. However, those
with a deﬁnitive diagnosis of SSc according to the ACR criteria who
developed inﬂammatory myopathy or secondary Sjögren’s syn-
drome were not excluded from the sample. All patients provided
written informed consent prior to study enrollment.
The control group comprised 147 healthy voluntary bone mar-
row donors recruited from the Hospital de Clínicas de Porto Alegre
blood bank. All donors were unrelated subjects of European and/or
African ancestry, and most lived in the urban area of Porto Alegre.
Individuals with any chronic or acute diseases were excluded from
the sample, as were those with a family history of genetic diseases
(X-linked, autosomal or chromosomal abnormalities). Native Bra-
zilians and subjects with Asian ancestry were not included. All con-
trols provided written informed consent for participation in the
study.
3. Clinical evaluation
All patients were interviewed and examined according to an
extensive questionnaire designed to assess end-organ damage
[12]. Disease subtype was classiﬁed as follows: diffuse cutaneous
SSc (truncal and acral skin tautness), limited cutaneous SSc (skin
tautness restricted to extremities and/or the face), and limited
SSc (systemic sclerosis sine scleroderma) [11,13]. Clinical charac-
teristics of the disease were observed and recorded as described
elsewhere [12]. Blood samples were collected for serology (antinu-
clear, anticentromere and antitopoisomerase I antibodies) and
DNA extraction. High-resolution computed tomography (HRCT)
of the lung was performed in most patients. Doppler echocardiog-
raphy was used to estimate pulmonary systolic arterial pressure
(PSAP), and patients with PSAPP 40 mm Hg were diagnosed with
pulmonary hypertension. The study was approved by the Research
Ethics Committee of the Hospital de Clínicas de Porto Alegre.4. Genomic DNA extraction
Genomic DNA was extracted from peripheral blood leukocytes
using a modiﬁed salting out technique, as described by Miller
et al. [14].
4.1. CXCL8. (251) T/A and CXCR2 (+1208) C/T genotyping
CXCL8 and CXCR2 genes were typed in patients and controls
using the polymerase chain reaction with sequence-speciﬁc prim-
ers (PCR-SSP) method, as described by Sarvestani et al. [15]. As an
internal control, b-globin-speciﬁc primers were included in the
PCR-SSP. For CXCL8 genotyping, 10 ll of PCR reaction mixture—
consisting of 250 ng of genomic DNA, 200 mmol/L dNTPs,
2.25 mM MgCl2, 1  Taq DNA polymerase buffer, 2 units of Taq
DNA polymerase, 10 pmol of each test primer, and 5 pmol of inter-
nal control primers—were employed. This was followed by a
touchdown procedure, which consisted of 25 s at 95 C, annealing
for 45 s at temperatures decreasing from 68 C (4 cycles) to 61 C
(20 cycles), and an extension step at 72 C for 40 s. The annealing
temperature for the remaining 5 cycles was 58 C for 40 s. Deter-
mination of CXCR2 gene polymorphisms was carried out using
the same PCR reaction mixture, except that the concentration of
MgCl2 was 1.7 mM. The touchdown procedure was also similar
to CXCL8 genotyping, but using annealing temperatures of 70, 65,
and 55 C in the three consecutive steps respectively. The reaction
products of CXCL8 and CXCR2 gene ampliﬁcation were separated
on 2.5% agarose gel and stained with ethidium bromide.
4.2. Statistical analysis
Data were analyzed using the EPI-INFO 6.0 and SPSS 11.0 soft-
ware packages. Carrier frequencies (CF) for the alleles and their
combinations were calculated and expressed as percentages. CFs
were compared using Yates’s chi-squared test or Fisher’s exact test.
Student’s t test and the Mann–Whitney U were used for between-
group comparisons in which the dependent variables were para-
metric and non-parametric, respectively. Holm’s procedure for
adjustment of P-values for multiple comparisons was applied with
the aid of the WinPepi software. Crude and Mantel–Haenszel odds
ratios (OR), with 95% conﬁdence intervals, were calculated for al-
leles or combinations whose CF distributions were signiﬁcantly
different between patients and controls. The sample size was cal-
culated, using the WinPepi software, for a signiﬁcance level of
0.05 and a statistical power of 93.71%.5. Results
The genotype distribution and allele frequencies for the CXCL8
(251) T/A and CXCR2 (+1208) C/T polymorphisms in SSc patients
and controls are presented in Table 1. The allele frequencies of
CXCL8 and CXCR2 genes were in Hardy–Weinberg equilibrium in
patients and controls alike. No signiﬁcant difference was found in
the frequencies of the CXCL8 (251) T/A and CXCR2 (+1208) C/T
alleles.
In our study, we observed a high frequency of CXCR2 (+1208)
CC carrier status in SSc patients (44.4% vs 22.4% in controls;
OR = 2.76; 95%CI = 1.62–4.72; P < 0.001) and a low frequency of
CXCR2 (+1208) TC carrier status (55.1% in controls vs. 23.8% in
SSc patients; OR = 0.26; 95%CI = 0.15–0.43; P < 0.001). There were
no signiﬁcant differences between SSc patients and controls with
regard to frequency of the CXCL8 (251) TT, TA and AA genotypes.
However, we did observe a high frequency of the CXCL8 (251) T
allele in association with the CXCR2 (+1208) CC genotype in con-
trols (100% in controls and 70.1% in SSc; adjusted OR = 0.03;
Table 1
Alleles and genotype distribution of the CXCR2 and CXCL8 single-nucleotide
polymorphisms in the systemic sclerosis (151) and healthy controls (147)
Healthy control Systematic sclerosis P-value*
n % n %
CXCR21208)
T 147 50.0 132 43.7 NS
C 147 50.0 170 56.3 NS
TT 33 22.4 48 31.8
TC 81 55.1 36 23.8 <0.001
CC 33 22.4 67 44.4
CXCL8251)
T 146 49.7 167 55.3 NS
A 148 50.3 135 44.7 NS
TT 37 25.2 56 37.1
TA 72 49.0 55 36.4 NS
AA 38 25.9 40 26.5
* P-values of alleles were calculated by Fischer’s exact test and genotypes by chi-
squared test.
Table 2
Correlation between CXCR2 and CXCL8 in healthy controls (147) and systematic
sclerosis (151).
Healthy control Systemic sclerosis P-value*
n % n %
CXCR2 TT
CXCL8 T+ 18 54.5 33 68.8 NS
CXCL8 A+ 33 100.0 28 58.3 <0.001
CXCL8 TT 0 0.0 20 41.7 <0.001
CXCL8 TA 18 54.5 13 27.1
CXCL8 AA 15 45.5 15 31.3
CXCR2 TC
CXCL8 T+ 58 71.6 31 86.1 NS
CXCL8 A+ 77 95.1 27 75.0 0.004
CXCL8 TT 4 4.9 9 25.0 0.003
CXCL8 TA 54 66.7 22 61.1
CXCL8 AA 23 28.4 5 13.9
CXCR2 CC
CXCL8 T+ 33 100.0 47 70.1 <0.001
CXCL8 A+ 0 0.0 40 59.7 <0.001
CXCL8 TT 33 100.0 27 40.3 <0.001
CXCL8 TA 0 0.0 20 29.9
CXCL8 AA 0 0.0 20 29.9
* Chi-Square Test or Fischer’s Exact Test.
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of the CXCL8 (251) TT and CXCR2 (+1208) CC genotypes was
more frequent in healthy controls than in SSc patients (100%
vs 40.3% respectively; adjusted OR = 0.01; 95%CI = 0.0–0.17;
P < 0.001).
Furthermore, when we investigated the presence of the CXCL8
(251) A allele in the CXCR2 (+1208) CC genotype, we found a high
frequency in patients as compared to controls (59.7% vs. 0% respec-
tively; adjusted OR = 98.67; 95%CI = 6.04–1610.8; P < 0.001). The
same was observed in the combination of the CXCL8 (251) TA
and AA with the CXCR2 (+1208) CC genotype (29.9% in SSc vs. 0%
in controls; adjusted OR = 28.92; 95%CI = 1.76–474.8; P < 0.001).
Association of the CXCR2 (+1208) TT genotype with the A allele
of the CXCL8 (251) gene was less frequent in patients than in con-
trols (58.3% vs. 100% respectively; adjusted OR = 0.04, 95%CI = 0.0–
0.32, P < 0.001). Similarly, the combination of the CXCL8 (251) TA
genotype and CXCR2 (+1208) TT genotype was less frequent in pa-
tients (27.1% vs. 54.5% in controls; OR = 0.31; 95%CI = 0.11–0.87;P = 0.02). Conversely, the combination of the CXCL8 (251) TT
genotype and CXCR2 (+1208) TT genotype was more frequent in
SSc patients (41.7% vs. 0% in controls; adjusted OR = 48.19;
95%CI = 2.91–798.7; P < 0.001). Finally, presence of CXCR2 + 1208
T in the absence of CXCL8–251 A (CXCR2 T+/CXCL8 A-) was more
frequent in patients than in controls (34.5% versus 3.5% respec-
tively; P < 0.001, OR = 14.50, 95%CI = 5.04–41.40). No signiﬁcant
between-group differences were found in the combination of the
CXCL8 (251) AA genotype and CXCL8 (251) T allele with the
CXCR2 (+1208) TT genotype.
Presence of the CXCL8 (251) A allele in the CXCR2 (+1208) TC
genotype was signiﬁcantly less frequent in patients as compared to
controls (75.0% and 95.1% respectively; OR = 0.16, 95%CI = 0.03–
0.63, P = 0.004). Furthermore, the combination of the CXCL8
(-251) TT genotype and CXCR2 (+1208) TC genotype was more fre-
quent in SSc patients than in controls (25% vs. 4.9% respectively;
OR = 6.42, 95%CI = 1.6–30.3, P = 0.003). No association was ob-
served with the CXCL8 (251) T / TT / AA genotype in combination
with the CXCR2 (+1208) TC genotype.
When clinical and laboratory data of the SSc patients were com-
pared, no signiﬁcant differences in CXCL8 (251) and CXCR2
(+1208) gene frequencies were found with regard to the severity
of skin disease, disease subtype, interstitial and vascular pulmon-
ary involvement, or autoantibody proﬁle.6. Discussion
The approximately 50 known human chemokines are grouped
into four families on the basis of conserved cysteine residues near
their N-terminus, and are designated as the CC, CXC, C, and CX3C
subfamilies. The CXC chemokine ligands are further subdivided
on the basis of the presence or absence of another three-amino
acid sequence, glutamic acid–leucine–arginine (the ELR sequence
motif), immediately proximal to the CXC sequence [16]. The ELR-
positive CXC chemokines, which include interleukin-8 (CXCL8),
are potent neutrophil chemoattractants. The chemokine-receptor
binding initiates a complex signaling cascade that generates che-
motactic responses, degranulation, release of ROS and changes in
the afﬁnity of cell surface integrins. [17]. CXCR1 and CXCR2 are
both expressed by endothelial cells, but only the expression of
CXCR2 is required for endothelial cell chemotaxis [18]. When the
function of CXCR2 is blocked, the response of endothelial cells to
CXCL8 is abrogated [19].
The importance of CXCL8 receptors for neutrophil migration
was demonstrated in a study with IL-8 receptor homologue knock-
out mice. In these animals, neutrophils failed to cross the epithe-
lium and accumulate in the subepithelial tissue [20]. In addition,
overexpression of CXCR2 has been considered an important factor
in inﬂammatory diseases such as rheumatoid arthritis, atheroscle-
rosis and psoriasis [21].
The CXCR2 gene polymorphism +1208 (T/C) has been investi-
gated as a factor in susceptibility to development of multiple scle-
rosis in Iranian individuals, but no signiﬁcant association was
found [22]. The polymorphisms +785 (C/T) and +1208 (T/C) also
showed no positive association with Behçet’s disease [23,24]. A
similar result was obtained by Breunis et al. [25], who found no
relationship between polymorphisms +1208 (T/C) or +1440 (G/A)
and Kawasaki disease. It should be noted that children with Kawa-
saki disease exhibit very high levels of proinﬂammatory cytokines
and chemokines, such as CXCL8 [26].
However, CXCR2 gene polymorphisms appear to be important
to the pathogenesis of diseases such as systemic sclerosis-associ-
ated ﬁbrosing alveolitis, because there was a signiﬁcantly higher
frequency of individuals with genotypes +785 CC and +1208 TT
in a group with this disease [9]. When frequency of the +785
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presence of the T allele was considered as a possible protective fac-
tor against pulmonary inﬂammation [27]. A similar protective ef-
fect was observed in relation to polymorphisms +1208 (T/C) and
+1440 (G/A), and the presence of diplotype 1208T/1440G repre-
sented a decreased risk of development of classic Kaposi’s sarcoma
(OR = 0.49, 95%CI = 0.30–0.78) [28].
Several polymorphisms in a given individual may contribute to
the individual risk of developing the disease. In our study, presence
the of CXCR2 T allele in the absence of the CXCL8 A allele (CXCR2
T+/CXCL8 A) was more frequent in patients than in controls
(OR = 14.50), suggesting an increased risk for the disease. The in-
verse was also true: the CXCL8 (251) A allele and TA genotype
in combination with CXCR2 (+1208) TT genotype were signiﬁcantly
more frequent in healthy controls (OR = 0.04 and OR = 0.31, respec-
tively), suggesting a protective effect. Conversely, the CXCL8
(251) TT genotype in association with CXCR2 (+1208) TT geno-
type was more frequent in SSc patients and suggested higher risk
of the disease (OR = 48.19).
The CXCR2 (+1208) T/C has the potential of altering mRNA pro-
cessing, stability or translation and is located in the 30 untranslated
region of exon 3 [8]. A previous study by Renzoni et al. [9] reported
an association between the presence of CXCR2 + 1208 T allele and
SSc (OR = 1.63). They also found this association to be greater when
the allele is homozygous (OR = 2.67). These ﬁndings were not con-
ﬁrmed in our study. We found a signiﬁcantly higher risk for sys-
temic sclerosis among carriers of the CXCR2 (+1208) CC genotype
(OR = 2.76) and a protective effect for carriers of the CXCR2
(+1208) TC genotype (OR = 0.26). Furthermore, we observed a sig-
niﬁcantly higher risk in the CXCR2 (+1208) CC genotype with
CXCL8 (251) A allele (OR = 98.67), as well as in combination with
the CXCL8 (251) TA genotype (OR = 28.92) and CXCL8 (251) AA
genotype (OR = 28.92). Conversely, the CXCL8 (251) T allele and
TT genotype in combination with CXCR2 (+1208) CC was more fre-
quent in healthy controls, suggesting a protective effect (OR = 0.03
and OR = 0.01, respectively). Moreover, association between the
CXCR2 (+1208) TC genotype and CXCL8 (251) A allele was more
frequent in healthy controls (OR = 0.16), and association with the
CXCL8 (251) TT genotype was more frequent in SSc patients
(OR = 6.42). Further studies are still required to improve the under-
standing of how these genetic polymorphisms relate to the devel-
opment of SSc.
Renzoni et al. [9] strongly suggested a role for CXCR2 polymor-
phisms in the pathogenesis of SSc. Their study described the asso-
ciation between CXCR2 and SSc in the British population,
indicating that TT homozygosity is a risk factor for the disease.
Our study did not corroborate this ﬁnding; we identiﬁed CC homo-
zygosity as a potential risk factor. The Brazilian population is
known to be highly diverse. Intermarriage between the Portuguese
and Native Brazilians or African slaves was common in the ﬁrst
centuries of colonization. While the Portuguese people were his-
torically the major European ethnic group in Brazil, subsequent
waves of immigration have also contributed to the establishment
of a multiethnic population [29]. This would be a plausible expla-
nation for the difference between our ﬁndings and those of Renz-
oni et al. [9]. At any rate, our study evaluated the interaction
between CXCL8 and its receptor, CXCR2, while Renzoni et al. [9]
did not.
To date, no study has described an association between pres-
ence of the CXCL8 (251) promoter gene and SSc, and only Renzoni
et al. [9] have investigated the frequency of CXCR2 (+1208) in pa-
tients with SSc. In conclusion, we suggest that CXCR2 (+1208) in
association with CXCL8 (251) may play a role in the pathogenesis
of this disease. The presence of the A allele (CXCL8) in association
with the T allele (CXCR2) may contribute to protection against SSc,
while its absence may increase the risk of this disease. The C alleleof CXCR2 is inversely associated: the presence of the A allele of
CXCL8 increases the risk of SSc, whereas its absence protects
against the disease. Additional studies of other ethnically diverse
populations should be performed to ascertain whether this gene
could be a marker of SSc. Furthermore, other studies investigating
the functionality of the CXCR2 and CXCL8 polymorphisms will be
required to achieve a better understanding of the results of disease
association studies.References
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